Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
2.
Rev Esp Quimioter ; 36(6): 625-628, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37721708

RESUMEN

OBJECTIVE: The prevalence of drug-resistant Neisseria gonorrhoeae (NG) infections is increasing. Studies report the prevalence of NG strains presenting A2059G/C2611T (rRNA23S) and S91F (parC) mutations conferring resistance to azithromycin and ciprofloxacin. METHODS: We conducted a prospective cohort study evaluating first void-urine urines, rectal, and oropharyngeal swabs collected from a cohort of patients in a tertiary hospital in Madrid between October 2022 and January 2023. Samples were screened by Allplex 7-STI Essential Assay (Seegene). Drug resistances were performed by Allplex NG-DR Assay (Seegene). RESULTS: A total of 1,415 patients were included, of which 112 had a positive sample for NG infection. One patient had a C2611T mutation (0.9%) and neither patient showed A2059G mutation. We found 67 (59.8%) S91F-positive patients. Forty-four patients (39.3%) not had any mutations. CONCLUSIONS: We report a low-prevalence of mutations A2059G/C2611T to macrolides and a high-prevalence to S91F in NG infections. Molecular methods for the detection of NG resistance could be useful in direct non-culturable samples.


Asunto(s)
Gonorrea , Neisseria gonorrhoeae , Humanos , Neisseria gonorrhoeae/genética , Fluoroquinolonas/farmacología , Fluoroquinolonas/uso terapéutico , Macrólidos/farmacología , Macrólidos/uso terapéutico , España/epidemiología , Prevalencia , Centros de Atención Terciaria , Estudios Prospectivos , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Gonorrea/tratamiento farmacológico , Gonorrea/epidemiología , Mutación , Farmacorresistencia Bacteriana/genética
4.
Rev Esp Quimioter ; 36(3): 310-313, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-36896655

RESUMEN

OBJECTIVE: Mycoplasma genitalium causes persistent sexually transmitted infections. The aims of this study were to estimate the prevalence of resistances to macrolides and fluoroquinolones in M. genitalium and the sexually transmitted coinfections in patients at Hospital Universitario La Paz (Madrid, Spain). METHODS: Patients attended between January and October 2021 were studied. Screening for sexually transmitted pathogens and detection of 23S rRNA and parC genes mutations were performed by real-time PCR (Allplex,SeegeneTM). RESULTS: A total of 1,518 females and 1,136 males were studied. The prevalence of M. genitalium was 2.1%. The macrolides resistance rate was 51.8%. The mutations found were A2059G, A2058T and A2058G. The rate of resistance to fluoroquinolones was 17.8% being the G248T mutation (S83I) the most frequent. Seven males had some sexual transmitted coinfection. CONCLUSIONS: Although the percentage of M. genitalium infections is low, the high rate of resistance to macrolides makes it necessary to revise the protocols for diagnosis and empirical treatment of sexually transmitted infections. The use of fluoroquinolones is appropriate after screening of macrolide resistance profile.


Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Masculino , Femenino , Humanos , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Fluoroquinolonas/farmacología , Fluoroquinolonas/uso terapéutico , Macrólidos/farmacología , Macrólidos/uso terapéutico , Mycoplasma genitalium/genética , Prevalencia , España/epidemiología , Centros de Atención Terciaria , Farmacorresistencia Bacteriana/genética , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/epidemiología , Mutación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA